healthcareassoci
infect
common
advers
event
hospit
respons
substanti
morbid
mortal
cost
accord
pointpreval
survey
conduct
hospit
pneumonia
frequent
healthcareassoci
infect
unit
state
preval
remain
rel
stabl
last
year
compar
substanti
reduct
nosocomi
infect
surgic
site
urinari
tract
infect
among
healthcareassoci
infect
pneumonia
lead
caus
death
studi
pediatr
hospit
describ
preval
healthcareassoci
infect
hap
respons
total
infect
patient
hap
increas
morbid
mortal
especi
case
ventilatorassoci
pneumonia
associ
longer
durat
mechan
ventil
hospit
stay
excess
crude
mortal
increas
hospit
cost
usd
per
case
recent
year
increas
recognit
respiratori
virus
caus
agent
hap
first
outbreak
report
later
preval
studi
latter
made
possibl
thank
implement
multiplex
polymeras
chain
reaction
pcr
detect
respiratori
virus
high
sensit
diagnost
specif
adult
respiratori
virus
report
case
hap
import
respiratori
virus
caus
pneumonia
hospit
children
highlight
retrospect
studi
outbreak
report
howev
inform
frequenc
outcom
viral
hap
pediatr
popul
scarc
incid
evolut
use
pcr
technolog
describ
prospect
studi
object
studi
describ
incid
hap
viral
etiolog
pediatr
patient
compar
clinic
characterist
outcom
patient
nvhap
sampl
process
use
rtpcr
system
microarray
visual
pneumovir
genomica
spain
capabl
detect
adenoviru
bocaviru
coronaviru
rhinovirusenteroviru
influenza
viru
subtyp
influenza
viru
b
metapneumoviru
subtyp
b
parainfluenza
viru
subtyp
b
respiratori
syncyti
viru
type
rsva
b
rsvb
sensit
depend
viru
patient
divid
two
group
accord
result
nasopharyng
sampl
patient
least
one
respiratori
viru
detect
includ
vahap
group
patient
respiratori
viru
detect
includ
nvhap
group
version
spss
packag
use
quantit
variabl
express
measur
central
tendenc
dispers
kolmogorovsmirnov
normal
test
perform
determin
variabl
normal
distribut
chisquar
test
fisher
exact
test
use
comparison
categor
variabl
mannwhitney
u
test
quantit
data
p
consid
statist
signific
measur
frequenc
diseas
incid
rate
vahap
estim
ci
use
logist
regress
estim
risk
advers
outcom
icu
admiss
mechan
ventil
mortal
also
develop
kaplan
meier
analysi
address
mortal
group
studi
period
patient
follow
patientday
ventilatorday
eightyeight
patient
met
cdc
criteria
hap
incid
rate
patient
day
c
ventil
associatedpneumonia
ventil
day
three
patient
die
procur
nasopharyng
sampl
patient
provid
consent
patient
possibl
obtain
nasopharyng
sampl
within
day
onset
clinic
symptom
figur
therefor
patient
includ
data
patientday
collect
baselin
epidemiolog
clinic
characterist
differ
includ
exclud
subject
tabl
includ
patient
male
median
age
month
old
iqr
none
includ
patient
refer
influenza
vaccin
previou
present
season
frequent
diagnos
malign
neoplasm
congenit
heart
diseas
malform
genitourinari
tract
twelv
case
hap
acquir
icu
least
one
respiratori
viru
detect
ci
hap
episod
singl
viral
pathogen
observ
coinfect
two
virus
case
frequent
identifi
virus
rsv
parainfluenza
repres
case
follow
influenza
b
rhinoviru
bocaviru
adenoviru
human
metapneumoviru
enteroviru
figur
patient
vahap
slightli
younger
median
age
iqr
vs
iqr
month
hospit
shorter
period
time
median
length
stay
iqr
vs
iqr
day
like
leukopenia
vs
nvhap
howev
strength
evid
differ
low
p
otherwis
epidemiolog
clinic
characterist
similar
two
group
tabl
median
length
antibiot
prescript
although
lower
vahap
group
show
signific
differ
two
group
tabl
blood
cultur
taken
patient
obtain
total
cultur
tracheal
aspir
cultur
obtain
patient
tracheal
intub
twelv
patient
either
posit
blood
tracheal
aspir
cultur
tabl
differ
number
blood
cultur
tracheal
aspir
taken
nvhap
group
vahap
group
p
eight
differ
bacteri
pathogen
isol
patient
order
frequenc
staphylococcu
epidermidi
n
pseudomona
aeruginosa
n
escherichia
coli
n
klebsiella
pneumonia
n
staphylococcu
aureu
n
stenotrophomona
maltophilia
n
enterobact
cloaca
n
acinetobact
baumanii
n
crp
procalcitonin
obtain
patient
includ
analysi
regard
outcom
tabl
two
third
patient
nvhap
almost
half
vahap
group
requir
mechan
ventil
vs
rr
ci
although
death
occur
slightli
earlier
nvhap
group
mortal
rate
show
signific
differ
group
figur
risk
death
differ
group
univari
multivari
analysi
rr
ci
first
prospect
studi
evalu
incid
nosocomi
pneumonia
viral
etiolog
pediatr
set
importantli
least
one
respiratori
viru
identifi
almost
two
third
patient
hap
morbid
outcom
addit
find
signific
differ
clinic
present
outcom
compar
vahap
nvhap
noninfluenza
respiratori
virus
predomin
accord
result
children
hap
posit
respiratori
viru
nasopharyng
specimen
import
respiratori
virus
children
respiratori
infect
discuss
first
wenzel
nosocomi
pneumonia
valenti
et
al
retrospect
studi
least
one
respiratori
viru
identifi
pediatr
patient
nosocomi
pneumonia
recent
retrospect
analysi
carri
singl
center
washington
identifi
least
one
respiratori
viru
adult
nonventil
hap
higher
frequenc
respiratori
virus
found
studi
could
due
systemat
activ
surveil
nosocomi
pneumonia
compar
studi
valenti
et
al
avail
molecular
method
increas
sensit
detect
respiratori
virus
studi
identifi
epidemiolog
clinic
characterist
could
reliabl
distinguish
pediatr
patient
respiratori
viru
infect
among
hap
howev
might
explain
low
case
number
popul
explor
larger
studi
median
length
stay
time
onset
pneumonia
shorter
patient
vahap
among
nvhap
wide
overlap
distribut
variabl
high
incid
morbid
outcom
admiss
intens
care
mechan
ventil
death
group
suggest
regardless
particip
respiratori
virus
outcom
hap
popul
advers
two
death
attribut
hap
accord
attend
physician
two
case
adenoviru
detect
one
die
methicillinresist
staphylococcu
aureu
septicemia
day
diagnosi
influenza
due
wellknown
associ
staphylococcu
aureu
infect
previou
episod
influenza
assum
respiratori
virus
also
contribut
death
patient
onethird
patient
vahap
studi
requir
admiss
icu
choi
report
third
adult
hap
requir
admiss
intens
therapi
present
least
one
type
respiratori
viru
previous
mention
studi
adult
nonventil
hap
washington
shorr
et
al
report
outcom
similar
patient
viral
bacteri
pneumonia
almost
half
patient
vahap
studi
requir
mechan
ventil
point
sever
nosocomi
pneumonia
associ
respiratori
virus
howev
studi
power
find
differ
outcom
group
final
respiratori
virus
influenza
compris
case
vahap
one
half
case
nosocomi
pneumonia
coincid
find
previou
studi
main
virus
identifi
patient
hap
rhinoviru
respiratori
syncyti
viru
parainfluenza
coronaviru
highlight
relev
infect
control
measur
prevent
spread
respiratori
virus
patient
caregiv
healthcar
personnel
focus
individu
influenzalik
ill
also
common
cold
respiratori
symptom
also
highlight
import
develop
effect
vaccin
drug
therapi
respiratori
virus
influenza
given
current
scarciti
prevent
therapeut
intervent
despit
lack
specif
treatment
case
vahap
routin
identif
respiratori
virus
patient
could
use
support
decis
withhold
stop
antibiot
certain
case
evid
bacteri
infect
potenti
reduc
advers
effect
cost
drug
resist
present
studi
present
certain
limit
patient
hap
includ
studi
howev
compar
baselin
characterist
subject
includ
statist
signific
differ
observ
tabl
support
repres
sampl
hand
test
broncho
alveolar
lavag
broncho
alveolar
brush
could
increas
sensit
bacteria
scarc
perform
consid
invas
essenti
patient
care
although
difficult
overcom
could
import
limit
abl
assur
infect
sole
due
viral
etiolog
addit
interfer
manag
patient
therefor
frequenc
test
other
pct
crp
alter
studi
studi
routin
use
pct
marker
bacteri
infect
need
anoth
issu
clarifi
studi
clinic
implic
type
respiratori
virus
sinc
ie
influenza
srv
consid
clinic
relev
often
other
parainfluenza
type
rhinoviru
studi
power
detect
differ
lastli
studi
conduct
tertiari
care
hospit
nonhomogen
sampl
patient
two
third
particip
least
one
known
risk
factor
viral
pneumonia
chronic
lung
diseas
congenit
heart
diseas
neoplasia
result
obtain
taken
account
context
necessarili
gener
pediatr
patient
hap
conclus
found
high
preval
respiratori
viru
infect
among
children
hap
therefor
necessari
implement
prevent
measur
reduc
burden
agent
consid
strategi
optim
antibiot
use
group
patient
develop
new
vaccin
drug
prevent
treatment
respiratori
virus
influenza
would
potenti
major
benefit
children
hap
larger
studi
differ
hospit
set
need
better
defin
clinic
spectrum
viral
hap
dataset
gener
studi
includ
manuscript
andor
supplementari
file
studi
carri
accord
recommend
norma
ofici
mexicana
committe
research
ethic
biosafeti
hospit
infantil
de
federico
written
inform
consent
subject
subject
gave
written
inform
consent
accord
declar
helsinki
protocol
approv
committe
research
ethic
biosafeti
hospit
infantil
de
federico
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
